Boehringer Ingelheim

Clinical Benchmarks: Comparing Retatrutide, Zepbound, and Survodutide

The race to dominate the obesity market is no longer just about the number on the scale; it is becoming a battle over metabolic quality and clinical duration. As new drugs emerge, the hierarchy of weight loss efficacy is being redefined by dual-agonist compounds that target multiple hormonal pathways. While current stars like Zepbound lead the pack in raw percentage points, the arrival of a “new generation” of injectables is creating a crowded field of high-performance competitors. According to Le Quotidien du Pharmacien, Boehringer Ingelheim’s survodutide has already demonstrated a 16.6% weight loss in international phase 3 trials for adults without type 2 diabetes.

Citi Dismisses Investor Concerns Over Retatrutide Side Effects

Despite the impressive weight loss figures, some investors have raised alarms regarding dysesthesia—a tingling sensation reported by some trial participants. However, Boursorama reports that Citi considers these concerns “exaggerated.” Data from advanced phase trials shows that dysesthesia occurred in approximately 12.5% of patients receiving the highest dose of retatrutide. Citi noted that these cases were mostly light to moderate, generally resolved during treatment, and rarely caused patients to stop taking the drug. The brokerage firm further suggested that this sensation is a known class effect of weight-loss medications rather than a problem unique to Lilly’s compound. Lilly is expected to present more granular safety data and secondary endpoints at a diabetes congress held between June 5 and June 8, 2026. Analysts suggest that if this data differentiates retatrutide from existing products, it could significantly boost market estimates, supporting Citi’s “buy” recommendation and a $1,500 price target.

The Risk of Muscle Mass Loss Under GLP-1s

As the industry celebrates massive weight reduction, a critical clinical shadow looms over the entire class of drugs. When patients lose weight rapidly via GLP-1 agonists, a significant portion of that loss may not be fat. Evidence suggests that up to 40% of the weight lost on these treatments can consist of lean muscle mass. This metabolic trade-off carries serious long-term health implications.

“Many patients on GLP-1s are faced with a loss of muscle mass, a common side effect that can lead to an increased risk of cardiovascular disease and a decrease in basal metabolism.”

The director of the diabetes research center at Massachusetts General Hospital, via Homéophyto This risk is driving a shift in how researchers evaluate success. The goal is moving away from total kilograms lost toward a more nuanced focus on body composition and the preservation of metabolic health.

Survodutide’s Focus on Visceral and Liver Fat

Boehringer Ingelheim’s survodutide is positioning itself to compete by targeting specific types of fat that drive metabolic disease. By activating both GLP-1 and glucagon receptors, the drug aims to reduce abdominal and potentially hepatic (liver) fat. In the SYNCHRONIZE-1 trial, the reduction in waist circumference served as a key marker for decreased abdominal fat and lower cardio-metabolic risk. While survodutide’s 16.6% weight loss does not dethrone Zepbound’s 20.9% in raw numbers, its ability to target inflammation and liver steatosis offers a distinct clinical angle. Ultimately, the long-term winner may not be the drug that achieves the highest percentage of weight loss, but the one that patients can sustain. As bariatric surgeon Hector Perez noted, “in real life, the best medicine is often the one patients can actually take.” As Eli Lilly works to prove that retatrutide can also reduce sleep apnea, the competition will likely hinge on who can offer the most stable, muscle-sparing, and metabolically healthy weight loss profile. For now, clinicians and patients alike are watching the upcoming diabetes congress data to see if these next-generation drugs can truly solve the complexities of obesity. Consult your healthcare provider regarding any new weight management medications or clinical trials.